<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03544905</url>
  </required_header>
  <id_info>
    <org_study_id>CYH33-101</org_study_id>
    <nct_id>NCT03544905</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33</brief_title>
  <official_title>A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients, and to Evaluate the Safety and Preliminary Efficacy in Advanced Esophagus Canver and Squamous Cell Carcinoma of the Esophageal Junction Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ShangHai HaiHe Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ShangHai HaiHe Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension
      Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary
      Efficacy of CYH33 in Advanced Solid Tumors Patients, and to Evaluate the Safety and
      Preliminary Efficacy in Advanced esophagus canver and Squamous cell carcinoma of the
      esophageal junction patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Anticipated">August 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD(Max tolerance does)</measure>
    <time_frame>35 days</time_frame>
    <description>To evaluate the MTD in patients with advanced solid tumor</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Advanced Esophagus Cancer and Squamous Cell Carcinoma of the Esophageal Junction</condition>
  <arm_group>
    <arm_group_label>Dose escalation study of CYH33</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the maximum tolerated dose (MTD) of CYH33</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYH33 for tablet</intervention_name>
    <description>1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)</description>
    <arm_group_label>Dose escalation study of CYH33</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  main inclusion:

               1. Evidence of a personally signed informed consent document;

               2. Male and/or female subjects above the ages of 18 years;

               3. Locally advanced or metastatic solid tumor patients who have failed or relapsed
                  on current standard of care for Phase 1a;

               4. Subject may provide Tumor tissue section(at least 8 pieces) if they agree;

               5. ECOG performance score 0-1;

               6. Life expectancy â‰¥ 12 weeks;

               7. At least 1 measurable target lesion on the baseline scan as per RECIST 1.1

        Exclusion Criteria:

          -  main criteria:

               1. prior received anti-tumor treatment, including anticancer drugs for the treatment
                  within 28 days of first dose of study treatment;

               2. Prior or concomitant other malignant tumor;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruihua Xu, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruihua Xu, M.D</last_name>
    <phone>86-20-87343804</phone>
    <email>ruihxu@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Rui hua, MD</last_name>
      <phone>13922206676</phone>
      <email>xurh@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>June 7, 2018</last_update_submitted>
  <last_update_submitted_qc>June 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

